Elsevier

Leukemia Research

Volume 22, Issue 12, December 1998, Pages 1085-1096
Leukemia Research

Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia

https://doi.org/10.1016/S0145-2126(98)00113-1Get rights and content

Abstract

Over the last two decades considerable knowledge has been acquired about the distribution of cell types within the dominant leukemic (Ph+/BCR-ABL+) clone that results in human chronic myeloid leukemia (CML). Evidence is now growing to indicate that three key biological changes affecting the development of such clones are: (1) an increased probability of differentiation at the level of the most primitive leukemic stem cells; (2) an increased turnover rate of the leukemic progenitors at all stages of differentiation; and (3) their increased ability to survive under conditions of factor-deprivation. Such a model explains the long latent period for the development of CML as well as why normal stem cells may persist in large numbers but still fail to compete in contributing to the daily output of mature blood cells in patients with disease. The recent development of new genetic and transplant models of human CML may now allow the molecular basis of these biological disturbances to be delineated and more effective therapeutic strategies developed.

Introduction

The biology of chronic myeloid leukemia (CML) has fascinated and frustrated experimental hematologists for several decades. The fascination is triggered by several important and unique features of CML (Table 1). One of these is the clear delineation of the disease course in most patients into two phases: an initial chronic phase which is typically prolonged (years) and a later blast crisis which is usually untreatable and rapidly fatal. Because of the gross overproduction of granulocytes and sometimes platelets that occurs during the initial chronic phase, most patients become symptomatic and are diagnosed at this point. Accordingly, their cells can be readily obtained in large numbers and studied. Also, the `leukemic' cells present in patients with chronic phase CML differentiate normally. Therefore, current methodologies for detecting and quantitating hematopoietic progenitors, which require their ultimate differentiation into recognizable elements, are readily applicable to CML progenitors 1, 2. Finally, because of the long median duration of the chronic phase (i.e. 3–6 years [3]), treatments that require time to become effective can be considered. Progression to blast crisis is associated with the acquisition of changes that impede or perturb the normal differentiation process and result in a rapid accumulation of undifferentiated blasts. These overwhelm continued normal blood cell output and are, themselves, typically refractory to conventional agents used to treat acute leukemia.

A second important feature of CML is its association with the presence in the affected cells of the Ph chromosome [4]. The formation of this chromosome is now known to result from a fusion of the BCR gene and the c-ABL gene and the creation of a functional oncogene [5]. This gene rearrangement provides an essential and stable marker for discriminating normal and leukemic cells in populations where both of these genotypes are present. This is particularly relevant to analyses of samples obtained from chronic phase patients in whom the `leukemic' cells are otherwise indistinguishable, in most respects, from their normal counterparts. In addition, the identification of the BCR-ABL gene as a unifying abnormality in CML has focused attention on the mechanisms by which its product, p210BCR-ABL, causes the pathology that is characteristic of the disease.

The third feature of CML that makes it an attractive paradigm to study is the presumed origin of the leukemic cells in a hematopoietic stem cell with lymphoid as well as myeloid differentiation potential. This is inferred from the molecularly unique feature of the BCR-ABL gene rearrangement in the cells from each CML patient [5], thus proving that the BCR-ABL+ cells present must indeed arise from a single cell in each case. The fact that this initial cell is then able to continue generating recognizable lymphoid and myeloid progeny indefinitely (if not further altered) argues in favour of its undifferentiated state at the time when the BCR-ABL gene rearrangement occurred.

In summary, CML appears to arise in different individuals as a result of the same rare genetic event occurring in a member of the developmentally most interesting population of the hematopoietic system. This leads to a clonal expansion of the affected cell without interference in its ability to differentiate into essentially normal progeny causing an initially, relatively benign disease to develop. Nevertheless, in spite of the interest and opportunities this situation provides, most CML patients die within 6 years of their diagnosis because they are ineligible for, or refractory to, the only two treatment modalities shown unequivocally to offer longer term benefits, i.e. allogeneic marrow transplantation and the administration of high doses of α-interferon [6]. Disappointingly, knowledge of the underlying genetic lesion has not, even after more than a dozen years, revolutionized our understanding of what goes wrong or how to effectively interfere with or exploit such information. In fact, some of the most promising therapeutic developments now being pursued using autotransplants are based more on the discovery in the early 1980s of a large but suppressed population of residual normal stem cells in most CML patients at diagnosis [6].

On the other hand, a growing knowledge of the biological behaviour of primitive normal hematopoietic cells, and improved methods for their purification, measurement and manipulation is allowing a more refined picture of the abnormalities that characterize primitive CML cells to be delineated. In this review, we will summarize the current status of the information that our group has obtained in this area and a resultant model of how we think the neoplastic hematopoiesis in patients with CML is deregulated.

Section snippets

CML considered as a problem in cell traffic control

Current thinking views hematopoiesis as a one directional linear branching system involving a huge expansion of cell numbers and a finely tuned output of mature end cells with many potential intervening points of regulation. These serve to alter either the number or proportion of cells available for subsequent amplification. The number of cells available at any given place in the system for further amplification is dictated by the activation (or maintenance) of biochemical events that control

The hematopoietic hierarchy

Four classes of hematopoietic cells are now typically distinguished. These include: (1) terminally differentiating cells that have acquired, to varying extents, the morphological features of the mature elements of the lineage they represent; (2) a number of more primitive and rare progenitor populations which are called colony-forming cells (CFC) because they can generate colonies of from 20 to more than 104 morphologically recognizable (mature) cells when stimulated in a semi-solid matrix to

Abnormalities in cellular behaviour

All Ph+/BCR-ABL+ progenitor populations, regardless of their differentiated state or lineage commitment, have been found to contain more proliferating cells than their counterparts in normal individuals, even prior to the administration of any therapy 1, 46. At the level of the CFC, this finding is consistent with the observation that the leukemic elements within the various subpopulations of CFC conventionally distinguished are, on average, similarly amplified in a given patient. In addition,

Summary

Chronic phase CML represents an example of quantitatively, rather than qualitatively, perturbed hematopoiesis. It is characterized by an inexorable, but kinetically, extremely slow rate of expansion of a Ph+/BCR-ABL+ stem cell population that frequently includes <105 LTC-IC by the time of diagnosis. Nevertheless, these cells are able to generate very large numbers of more differentiated cells (totalling >1012 cells). The latter include proportionately normal ratios of erythroid,

Acknowledgements

Much of the work discussed in this review was supported by grants from the National Cancer Institute of Canada (NCIC) with funds from the Terry Fox Run and the Canadian Cancer Society and a grant from Novartis (Basel, Switzerland). The authors also thank Mrs. K. Lambie for collating the updated progenitor data and Ms. Bernadine Fox for expert assistance in preparing the manuscript. C.J. Eaves is a Terry Fox Cancer Research Scientist of the NCIC.

References (86)

  • A.L Petzer et al.

    Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia

    Blood

    (1996)
  • A.L Petzer et al.

    Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia

    Blood

    (1997)
  • C Sirard et al.

    Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism

    Blood

    (1994)
  • M Ogawa et al.

    Renewal and commitment to differentiation of hemopoietic stem cells (an interpretive review)

    Blood

    (1983)
  • M Ogawa

    Differentiation and proliferation of hematopoietic stem cells

    Blood

    (1993)
  • A.A Fauser et al.

    Proliferative state of human pluripotent hemopoietic progenitors (CFU-GEMM) in normal individuals and under regenerative conditions after bone marrow transplantation

    Blood

    (1979)
  • J Cashman et al.

    Regulated proliferation of primitive hematopoietic progenitor cells in long-term human marrow cultures

    Blood

    (1985)
  • C.J Eaves et al.

    Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer

    Blood

    (1991)
  • G.K Sing et al.

    Transforming growth factor β selectively inhibits normal and leukemic human bone marrow cell growth in vitro

    Blood

    (1988)
  • H.E Broxmeyer et al.

    Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells

    Blood

    (1990)
  • J.L Guan et al.

    Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor α4β1

    Cell

    (1990)
  • J Lesley et al.

    CD44 and its interaction with extracellular matrix

    Adv Immunol

    (1993)
  • O.J Borge et al.

    Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin

    Blood

    (1997)
  • H.J Sutherland et al.

    Alternative mechanisms with and without Steel factor support primitive human hematopoiesis

    Blood

    (1993)
  • V Maguer-Satta et al.

    BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia

    Blood

    (1996)
  • A Bedi et al.

    BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia

    Blood

    (1993)
  • C Biernaux et al.

    Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals

    Blood

    (1995)
  • D.E Hogge et al.

    Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor

    Blood

    (1996)
  • Eaves CJ, Eaves AC. In: Goldman JH, guest editor. Chronic Myleoid Leukemia. Bailliere Tindall. London: Saunders,...
  • Eaves CJ, Eaves AC. In: Goldman JM, guest editor. Chronic Myeloid Leukemia. Bailliere's Clinical Haematology, London:...
  • Cortes J, Kantarjian HM, Giralt S, Talpaz M. In: Goldman MJ, guest editor. Chronic Myeloid Leukemia. Bailliere Tindall....
  • P.C Nowell et al.

    A minute chromosome in human chronic granulocytic leukemia

    Science

    (1960)
  • Groffen J, Heisterkamp N. In: Goldman JM, guest editor. Chronic Myeloid Leukemia. Bailliere Tindall. London: Saunders,...
  • A.M Carella et al.

    New insights in biology and current therapeutic options for patients with chronic myeloid leukemia

    Haematologica

    (1997)
  • Sutherland HJ, Eaves AC, Eaves CJ. In: Gee AP, editor. Bone Marrow Processing and Purging: A Practical Guide. Boca...
  • S.J Szilvassy et al.

    Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy

    Proc Natl Acad Sci USA

    (1990)
  • C.L Miller et al.

    Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability

    Proc Natl Acad Sci USA

    (1997)
  • E Conneally et al.

    Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice

    Proc Natl Acad Sci USA

    (1997)
  • C.M Baum et al.

    Isolation of a candidate human hematopoietic stem-cell population

    Proc Natl Acad Sci USA

    (1992)
  • M Nosten-Bertrand et al.

    Normal spatial learning despite regional inhibition of LTP in mice lacking Thy-1

    Nature

    (1996)
  • K Yoshida et al.

    Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders

    Proc Natl Acad Sci USA

    (1996)
  • E.F Srour et al.

    Relationship between cytokine-dependent cell cycle progression and MHC class II antigen expression by human CD34+HLA-DR− bone marrow cells

    J Immunol

    (1992)
  • C Eaves et al.

    The biology of normal and neoplastic stem cells in CML

    Leuk Lymphoma

    (1993)
  • Cited by (52)

    • A Prospective Analysis of Human Leukemogenesis

      2018, Stem Cell Reports
      Citation Excerpt :

      Not only was this discovery of a primarily quiescent subset of primitive CP-CML progenitors unexpected, to my knowledge, it was the first report of a reversibly dormant subset of malignant cells. On the other hand, despite their apparently “normal” proliferative state, the self-maintenance behavior of these primitive CP-CML cells in vitro, as shown by their reduced outputs of daughter long-term culture initiating cells, (LTC-ICs) proved to be highly deficient by comparison with their normal counterparts both in the presence and absence of stromal cells (Figure 2) (Eaves et al., 1998). Accordingly, our initial thoughts about how to engineer their progression to AML were focused on strategies to overcome this “self-renewal defect.”

    View all citing articles on Scopus
    View full text